Jacobs Levy Equity Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-463,593
| Closed | -$1.06M | – | 1077 |
|
|
2024
Q2 | $1.06M | Buy |
463,593
+85,735
| +23% | +$327K | ﹤0.01% | 730 |
|
|
2024
Q1 | $1.63M | Buy |
377,858
+64,790
| +21% | +$226K | 0.01% | 630 |
|
|
2023
Q4 | $955K | Sell |
313,068
-260,188
| -45% | -$489K | ﹤0.01% | 729 |
|
|
2023
Q3 | $825K | Buy |
573,256
+80,480
| +16% | +$156K | ﹤0.01% | 705 |
|
|
2023
Q2 | $1.23M | Buy |
492,776
+209,541
| +74% | +$572K | 0.01% | 661 |
|
|
2023
Q1 | $759K | Buy |
283,235
+190,189
| +204% | +$914K | ﹤0.01% | 746 |
|
|
2022
Q4 | $505K | Sell |
93,046
-9,472
| -9% | -$79.4K | ﹤0.01% | 791 |
|
|
2022
Q3 | $1.28M | Sell |
102,518
-303,546
| -75% | -$3.47M | 0.01% | 658 |
|
|
2022
Q2 | $2.01M | Buy |
+406,064
| New | +$2.25M | 0.02% | 598 |
|
|
2021
Q3 | – | Sell |
-10,989
| Closed | -$241K | – | 1137 |
|
|
2021
Q2 | $241K | Sell |
10,989
-28,297
| -72% | -$629K | ﹤0.01% | 958 |
|
|
2021
Q1 | $945K | Sell |
39,286
-88,797
| -69% | -$2.06M | 0.01% | 746 |
|
|
2020
Q4 | $2.3M | Buy |
128,083
+4,784
| +4% | +$71.5K | 0.02% | 551 |
|
|
2020
Q3 | $1.42M | Buy |
123,299
+67,041
| +119% | +$1.11M | 0.01% | 587 |
|
|
2020
Q2 | $1.36M | Buy |
56,258
+23,070
| +70% | +$382K | 0.01% | 602 |
|
|
2020
Q1 | $366K | Buy |
33,188
+23,761
| +252% | +$444K | ﹤0.01% | 801 |
|
|
2019
Q4 | $249K | Buy |
+9,427
| New | +$220K | ﹤0.01% | 903 |
|
Jacobs Levy Equity Management's GTHX Position: Q3 2024 in Review
Jacobs Levy Equity Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 463,593 shares — an estimated $1.06M sold.
Jacobs Levy Equity Management first reported a position in GTHX in Q4 2019 and held it in 16 quarters. The position peaked at $2.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Jacobs Levy Equity Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Jacobs Levy Equity Management sold 463,593 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.06M.
- Jacobs Levy Equity Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
- Jacobs Levy Equity Management's G1 Therapeutics, Inc. Common Stock position peaked at $2.3M in Q4 2020.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.